An investigation published by The BMJ today reveals widespread influence of food and drink brands in schools and nurseries – through breakfast clubs, nutrition guidance, and healthy eating campaigns –… read more.
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a… read more.
A new study by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with researchers at Harvard T.H. Chan School of Public… read more.
Researchers from the SUMMIT trial have reported that treatment with tirzepatide has reduced the risk of worsening heart failure and cardiovascular disease-related death for obese adults. The findings… read more.
Vitamin D supplements may lower blood pressure in older people with obesity and taking more than the Institutes of Medicine’s (IOM) recommended daily dose does not provide additional… read more.
Researchers report that the number of people in the U.S. who died from ischemic heart disease related to obesity increased by approximately 180% from 1999 to 2020. The… read more.
A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread… read more.
Young people diagnosed with severe obesity who had weight-loss surgery at age 19 or younger have achieved sustained weight loss 10 years later, researchers reported on Oct. 30,… read more.
All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced… read more.
A new type of blood test using lipids could make it easier to identify children at risk of complications around obesity including type two diabetes, liver and heart… read more.
Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is… read more.
Treatment with semaglutide and tirzepatide led to significant weight loss and improved blood sugar control in overweight or obese patients with type 1 diabetes (T1D). Researchers reported this… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
